Cytomegalovirus-vectored vaccines for HIV and other pathogens

Academic Article

Abstract

  • The use of cytomegalovirus (CMV) as a vaccine vector to express antigens against multiple infectious diseases, including simian immunodeficiency virus, Ebola virus, plasmodium, and mycobacterium tuberculosis, in rhesus macaques has generated extraordinary levels of protective immunity against subsequent pathogenic challenge. Moreover, the mechanisms of immune protection have altered paradigms about viral vector-mediated immunity against ectopically expressed vaccine antigens. Further optimization of CMV-vectored vaccines, particularly as this approach moves to human clinical trials will be augmented by a more complete understanding of how CMV engenders mechanisms of immune protection. This review summarizes the particulars of the specific CMV vaccine vector that has been used to date (rhesus CMV strain 68-1) in relation to CMV natural history.
  • Published In

  • AIDS  Journal
  • Digital Object Identifier (doi)

    Pubmed Id

  • 24019274
  • Author List

  • Barry PA; Deere JD; Yue Y; Chang WWL; Schmidt KA; Wussow F; Chiuppesi F; Diamond DJ; Sparger EE; Walter MR
  • Start Page

  • 335
  • End Page

  • 349
  • Volume

  • 34
  • Issue

  • 3